Redeye is intrigued by today’s news that Saniona has selected an additional clinical candidate, the GABAA α5 negative allosteric modulator SAN2465, for preclinical development. SAN2465 will target major depressive disorder, which again shows the broad potential of Saniona’s platform and the precision targeting of its drug candidates. Saniona indicates that the results will be discussed with potential partners, and we expect this program to be positioned for collaboration mainly. We will discuss the recent progress more closely in relation to our Q4 update at the latest.